Home Health & Wellness Pharmacists urged to take lead in clinical research and drug trials to advance healthcare outcomes

Pharmacists urged to take lead in clinical research and drug trials to advance healthcare outcomes

0
Pharmacists urged to take lead in clinical research and drug trials to advance healthcare outcomes

The Nigerian pharmaceutical landscape is currently undergoing a pivotal transformation, shifting from a focus on traditional supply-chain management and drug dispensing toward a more integrated, research-driven clinical practice. This paradigm shift took center stage during the Pharmaceutical Society of Nigeria’s (PSN) 99th Annual National Conference, tagged Ijele ’26, held in the industrial hub of Awka, Anambra State. During a key plenary session, the Director of Pharmacy at the Lagos State University Teaching Hospital (LASUTH), Pharm (Dr) Modupe Oyawole, issued a clarion call for pharmacists to occupy leadership roles within the clinical research and drug trial ecosystem.

Dr. Oyawole’s address, titled “Clinical Research and Trials Ecosystem: The Roles of Pharmacists,” serves as a cornerstone for the profession’s strategic roadmap in Nigeria. As the nation faces a rising burden of both communicable and non-communicable diseases, the integration of pharmacist-led research is being viewed not merely as an academic exercise, but as a critical requirement for enhancing patient safety, refining therapeutic protocols, and fostering local evidence-based medicine.

The Evolution of the Ijele ’26 Conference

The Ijele ’26 conference represents a landmark event for the Pharmaceutical Society of Nigeria, marking nearly a century of professional advocacy and healthcare service in the country. The choice of the theme, “Ijele”—an iconic, towering masquerade figure from Igbo culture—symbolized the immense growth, stature, and protective role the pharmacy profession plays within the Nigerian healthcare system.

The plenary session provided a platform for experts to dissect the complexities of the drug development lifecycle. With Nigeria increasingly becoming a destination for global clinical trials, the discourse underscored the necessity for local pharmacists to transition from mere participants to primary investigators and strategic leads. By leveraging their unique expertise in pharmacokinetics, pharmacogenomics, and clinical safety, pharmacists are positioned to bridge the gap between laboratory drug discovery and real-world clinical application.

Defining the Research Landscape: Distinctions and Responsibilities

To effectively lead, Dr. Oyawole emphasized the importance of distinguishing between clinical research and clinical trials. While the terms are frequently used interchangeably in public discourse, their regulatory and practical applications differ significantly. Clinical research is the broad umbrella encompassing observational studies, behavioral surveys, and the analysis of health data aimed at expanding the fundamental understanding of disease progression. In contrast, clinical trials are specialized, structured interventions designed specifically to evaluate the safety, efficacy, and dosage requirements of new therapeutic agents, vaccines, or medical devices.

“Every clinical trial is clinical research, but not all clinical research is a clinical trial,” Oyawole stated, clarifying that the two components form a continuous loop of evidence generation. This system begins at the molecular discovery phase, moves through preclinical testing, proceeds to rigorous clinical trials, and eventually culminates in regulatory assessment and post-marketing surveillance—a process where the pharmacist’s role is indispensable.

The Pharmacist as a Clinical Investigator

The core argument presented at the conference is that pharmacists possess the most intimate knowledge of medication-related problems. Because they interact with patients at the point of care, pharmacists are uniquely positioned to identify research questions that arise from daily clinical practice.

Pharmacists urged to take lead in clinical research, drug trials

The responsibilities identified for pharmacists within this ecosystem include:

  1. Medication Reconciliation: Ensuring that research participants are not exposed to adverse drug interactions, a role that safeguards the integrity of trial data.
  2. Pharmacokinetic Oversight: Utilizing expertise to manage drug dosing, monitor plasma concentrations, and interpret the clinical response to experimental therapies.
  3. Patient Advocacy and Adherence: Serving as the bridge between cold clinical data and the human experience, helping participants navigate the complexities of trial protocols while supporting treatment persistence.
  4. Precision Medicine: Utilizing pharmacogenomics to tailor treatments to individual genetic profiles, thereby minimizing adverse effects and optimizing therapeutic exposure.

Barriers to Institutional Integration

Despite the clear potential for pharmacists to lead, the conference highlighted significant systemic barriers. Dr. Oyawole’s assessment noted that the lack of institutional capacity remains a primary inhibitor. Key challenges identified include:

  • Infrastructure Deficits: A lack of specialized research facilities and standardized laboratories within many public hospitals.
  • Funding and Networking: Limited access to competitive grants and a lack of robust national networks that connect hospital-based pharmacists with industry sponsors.
  • Educational Gaps: A perceived need for more rigorous, specialized training in clinical trial management beyond the standard pharmacy curriculum.
  • Collaboration Hurdles: A weak interface between academic institutions and the pharmaceutical industry, which often prevents research findings from moving from the page to the pharmacy shelf.

Strategic Roadmap: From Observation to Leadership

The call to action provided by the LASUTH Director of Pharmacy is structured around five strategic pillars intended to empower the next generation of Nigerian pharmacist-researchers. First, pharmacists must transition from passive observers of medication issues to active generators of research inquiries. Second, they must integrate into existing research initiatives to build a track record of collaboration. Third, there is an urgent need for capacity-building through mentorship programs that pair junior pharmacists with experienced clinical investigators.

Fourth, pharmacists must aggressively pursue leadership roles, such as serving as Principal Investigators (PIs) or members of Institutional Review Boards (IRBs). Finally, the focus must shift toward translating these findings into actionable policies that improve patient care. As Oyawole aptly put it, the goal is not merely to have more pharmacists participating in research activities, but to produce pharmacists capable of shaping the direction of clinical research in Nigeria.

Implications for the Nigerian Healthcare System

The broader implications of this shift are profound. Nigeria’s dependence on imported pharmaceutical data and foreign-conducted clinical trials often limits the relevance of treatment protocols to the local population, whose genetic, environmental, and socio-economic factors may differ from those in the West or Asia. By leading clinical trials, Nigerian pharmacists can contribute to the development of “real-world evidence” that is specific to the local patient population.

Furthermore, as the global trend moves toward precision medicine, the role of the pharmacist as a medication expert becomes even more central. By mastering the ability to answer the question, “For whom does this medicine work, at what dose, and with what risk?” pharmacists effectively safeguard the public health interests of the nation.

Conclusion and Future Outlook

The plenary session at Ijele ’26 served as a catalyst for a new era of professional identity. The message was clear: if pharmacists are the custodians of medicine, they must also be the custodians of the evidence that justifies their use. As the profession looks toward the future, the integration of clinical research into the daily functions of the pharmacist will likely become the benchmark for professional excellence in Nigeria.

With stakeholders from academia, the pharmaceutical industry, and regulatory bodies present at the conference, the consensus appeared to be that the path to a more robust healthcare system lies in the empowerment of the pharmacist as a scientist. As the industry continues to evolve, the ability of Nigerian pharmacists to bridge the gap between clinical theory and bedside practice will be the deciding factor in the country’s journey toward medical self-reliance and improved patient outcomes. The challenge has been laid; the profession is now tasked with building the capacity to meet it.